SCHEDULE: Lifecore Biomedical: 22NW Fund Seeks Preferred Stock Redemption

22NW Fund has initiated a redemption process for its Series A Preferred Stock in Lifecore Biomedical, signaling a significant shift in its investment.

Summary

• This filing is an amendment to a Schedule 13D, indicating a change in beneficial ownership of Lifecore Biomedical, Inc. (the "Issuer").
• The reporting persons, primarily 22NW Fund, LP, and related entities and individuals, collectively hold approximately 6.74% of the Issuer's outstanding shares.
• This ownership stake includes 2,711,218 shares issuable upon the conversion of Series A Preferred Stock, which are convertible within 60 days of the filing date.
• On June 30, 2026, the reporting persons submitted an optional redemption notice for their entire holding of Series A Preferred Stock, plus accrued dividends.
• The redemption is set to occur on December 28, 2026, at which point the Issuer will purchase the Series A Preferred Stock for cash, and the reporting persons will no longer hold this class of stock.
• The Issuer's Form 10-Q filed on May 6, 2026, noted that cash redemption payments would require consent or waiver from its credit agreements.
• 22NW believes that if the Issuer restricts this redemption, it would contravene the terms of the Series A Preferred Stock's Certificate of Designations.
• 22NW intends to file a motion to amend its existing complaint against the Issuer and former directors/officers, alleging a breach of a Securities Purchase Agreement from January 9, 2023, related to the Series A Preferred Stock issuance.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the initiation of legal action and potential disputes over preferred stock redemption, indicating underlying financial or governance concerns.

Positives

• The reporting persons are exercising their contractual right to redeem their Series A Preferred Stock, which could result in a cash payout.
• The reporting persons hold a significant stake (6.74%) in Lifecore Biomedical, indicating a substantial investment.
• The conversion of Series A Preferred Stock into common stock within 60 days suggests a potential increase in common stock holdings if redemption is not fully executed.

Negatives

• The Issuer's credit agreements may restrict the cash redemption payments, potentially leading to a dispute.
• 22NW alleges that the Issuer may have breached a Securities Purchase Agreement related to the Series A Preferred Stock.
• The need to file a motion to amend a complaint indicates ongoing legal action and potential conflict with the Issuer's management and board.

Risks

• Potential legal disputes and litigation if the Issuer fails to honor the redemption notice due to credit agreement restrictions.
• The risk that the Issuer may not have sufficient cash to complete the redemption as per the terms of the Certificate of Designations.
• The possibility of further legal action and associated costs for both the reporting persons and the Issuer.
• Uncertainty regarding the Issuer's ability to secure necessary consents or waivers for the redemption payments.

Future Outlook

The future outlook for 22NW Fund involves the redemption of their Series A Preferred Stock by December 28, 2026, and potential legal action if the Issuer disputes or is unable to fulfill the redemption. The percentage of ownership is expected to decrease significantly upon successful redemption.

Management Comments

• "To make such cash redemption payments the Company would be required to obtain consent to such redemption payments or waiver of the restriction on cash dividends and/or redemptions set forth in each of the Company's credit agreements."
• 22NW believes that if the Issuer imposes this restriction on the redemption of its shares of Series A Preferred Stock it will be in contravention of the Certificate of Designations.
• 22NW intends to file a motion with the Supreme Court of the State of New York, County of New York to amend its outstanding Complaint against the Issuer and certain former directors and officers of the Issuer to, among other things, include a claim that when the Issuer entered into its current credit agreements in May 2023 it breached that certain Securities Purchase Agreement dated as of January 9, 2023, under which 22NW and other investors purchased the Series A Preferred Stock.

Industry Context

StockSavvy.ai notes that this filing highlights a common scenario in preferred stock investments where redemption clauses can become points of contention, especially if the issuing company faces financial constraints or restrictive debt covenants. The legal action indicates a potential governance or financial distress issue within Lifecore Biomedical.

Corporate Governance

Legal Proceedings

• 22NW intends to file a motion to amend its outstanding Complaint against Lifecore Biomedical and certain former directors and officers.
• The amended complaint will include a claim that the Issuer breached a Securities Purchase Agreement dated January 9, 2023, when entering into its current credit agreements in May 2023.

Stakeholder Impact

• Shareholders: Potential for increased legal costs and uncertainty if litigation proceeds. The redemption of preferred stock could impact the capital structure.
• Creditors: The Issuer's ability to meet redemption obligations may be constrained by existing credit agreements, potentially leading to covenant breaches or renegotiations.
• Investors in Series A Preferred Stock (22NW Fund): Exercising their right to redeem for cash, but facing potential resistance from the Issuer.
• Management/Board of Directors: Facing potential legal challenges and scrutiny over past agreements and current financial management.

Next Steps

• The reporting persons will await the redemption date of December 28, 2026, for their Series A Preferred Stock.
• 22NW intends to file a motion to amend its existing complaint against Lifecore Biomedical and former directors/officers.
• The Issuer will need to address the redemption notice, potentially seeking consent or waivers from its lenders.
• Potential for further legal proceedings if the redemption is contested or not fulfilled.

Key Dates

Recommendation

The filing indicates a significant stake being redeemed and potential legal disputes, creating uncertainty. While the redemption itself is a contractual right, the Issuer's potential inability or unwillingness to comply due to credit agreements introduces risk. A 'hold' recommendation is appropriate pending resolution of the redemption and legal proceedings, as the outcome could significantly impact the company's financial health and capital structure.

Keywords

Schedule 13D, Lifecore Biomedical, 22NW Fund, Series A Preferred Stock, Redemption, Beneficial Ownership, Securities Purchase Agreement, Litigation, Credit Agreements, SEC Filing